Back to search results

A Study of JNJ-88545223 for Active Psoriatic Arthritis

This study is testing a new medication called JNJ-88545223 for adults with active psoriatic arthritis (PsA). Researchers want to see if JNJ-88545223 works better than a placebo (an inactive substance) to reduce the signs and symptoms of PsA, and improve joint and skin health. To join, you must be at least 18 years old, have had PsA for at least 3 months, and have active disease with at least 3 swollen and 3 tender joints. The main goal is to see how many participants have a significant improvement in their PsA symptoms after 16 weeks of treatment. The current status of this study is unclear.

Study design
This is an interventional study involving approximately 240 participants. Participants will receive either JNJ-88545223 or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 16, indicating follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07321873

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

Recruiting
PHASE2Ages 18+InterventionalTreatment
Janssen Research & Development, LLC
~240 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:JNJ-88545223Placebo

At a glance

Recruiting sites
73 of 73 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Participants who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16
Measured over Week 16

Conditions

Arthritis, Psoriatic

Explore related trials

PsoriasisPsoriatic Arthritis

Where it's being run

73 sites across 18 states
Poland14
China10
Germany9
Hungary7
Czechia6
Japan6
Florida5
Spain5

Study leadership

  • Janssen Research & Development, LLC Clinical Trial · STUDY_DIRECTOR · Janssen Research & Development, LLC

Who to contact

Study Contact
[email protected]
844-434-4210
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening
Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (Week 0/Day 1) based on the 66/68 joint assessment; AND (b) C-reactive protein (CRP) greater than or equal to (\>=) 0.1 milligrams per deciliter (mg/dL) at screening from the central laboratory
Have \>= 1 of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
Have active plaque psoriasis with at least one psoriatic plaque of \>= 2 centimeter (cm) diameter or nail changes consistent with psoriasis
A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

Exclusion

Has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (except PsA), psychiatric, genitourinary, or metabolic disturbances
Has suspected or known allergies, hypersensitivity, or intolerance to JNJ-88545223 or excipients used in the investigational medicinal product (IMP), including placebo (JNJ-88545223 investigator's brochure); or has a history of severe allergic reaction, angioedema, or anaphylaxis to drugs or food
Has fibromyalgia or osteoarthritis symptoms that, in the opinion of the investigator, would have potential to interfere with efficacy assessments
Currently has a malignancy or has a history of malignancy within 5 years prior to screening

What this trial measures

  • Proportion of Participants who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16Week 16

    The ACR 50 responders are participants with an improvement of greater than or equal to (\>=) 50 percent (%) from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain visual analog scale \[VAS\], patient's global assessment of disease activity \[arthritis, VAS\] scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein).